Lilly's CGRP migraine drug gets the nod from NICE

18 November 2020

US pharma major Eli Lilly (NYSE: LLY) has announced that the UK National Institute for Health and Care Excellence (NICE) has recommended Emgality (galcanezumab) as an option for the prevention of migraine in adults with episodic and chronic migraine in England and Wales.

The decision is based on clinical trials comparing Emgality with placebo, in which the calcitonin gene-related peptide (CGRP) inhibitor halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more preventative medicines.

Gemma Jolly, Migraine Trust, head of information and support, said: “This is wonderful news for people living with this very painful and debilitating neurological condition. Both chronic and episodic migraine patients across England and Wales will be able to access an effective drug on the National Health Service that has been specifically designed to prevent migraine. Migraine significantly impacts the lives of those who live with it and access to this important new medication will be life-changing for many.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK